VIVO diagnostics buys Genyca and leads the way in precision diagnostics

21/06/2019
Diego Gutiérrez
VIVO diagnostics buys Genyca and leads the way in precision diagnostics

The VIVO diagnóstico group takes a further step on its way to becoming the leading company in precision diagnostics in Spain. The company enters the field of genetics, and has just formalised the incorporation of the Genyca group, a laboratory specialising in molecular genetics.

VIVID DIAGNOSIS

VIVO diagnosis is a company specialising in diagnostic imaging and telemedicineThe new system will be able to combine in vivo and in vitro diagnostics through the use of artificial intelligence and Big Data tools.

To this end, it carries out an analysis based on prediction, prevention and personalisation. For the group, it is essential to identify any signs or probability of change in people's state of health as early as possible and as accurately as possible.

Ahora, además, gracias a Genyca, se va a incorporar pruebas de diagnóstico genético molecular para ayudar a estudiar el genoma de cada individuo, también denominado por algunos líderes del sector como el “software del cuerpo humano”.

However, this is not VIVO diagnostics' first operation on the market. Its journey towards precision diagnostics and service to the public began two years ago with two other operations. mergers and acquisitions . The following are some of the issues that we set out below.

Dima Clinic

This clinic leader in breast pathology was the first of these. Dima Clinic has expert breast surgeons, radiologists and oncologists who offer comprehensive breast diagnosis and treatment.

Its experts assess each patient and her risk factors, using both mammography and breast ultrasound and obtaining the analysis of the results in an average of 2-3 days, as in these cases time is of the essence.

Fence

Después vino Cerco, una compañía referente en el mercado andaluz y with a strong presence in the world of clinical research.

In addition to mammography and breast ultrasound, its services include magnetic resonance imaging, CT and densitometry, with the aim of offering patients the highest diagnostic quality and reliability.

Lastest news

Notable technology M&A deals in Spain | Analysis: July 2026

El M&A tecnológico en España registró 44 operaciones identificadas en julio de 2026: 25 correspondieron a adquisiciones, fusiones, inversiones de capital privado (private equity), joint ventures o tomas de participación, mientras que 19 fueron rondas de venture...

Lyngsoe acquires CodeOne with Baker Tilly as advisor

In July 2026, Lyngsoe announced the acquisition of CodeOne, a Portuguese technology company specialising in software solutions, RFID, warehouse mobility, voice-enabled order picking, and automatic data capture and identification. Baker Tilly Tech...

Notable technology M&A deals in Spain | Analysis: June 2026

Technology M&A in Spain totalled 40 identified transactions by the end of June 2026, of which 21 were acquisitions, private equity investments, asset purchases or equity investments, whilst 19 were venture capital funding rounds. The...

Baker Tilly advises Misterplan on its sale to Partenea 

In May 2026, Partenea announced the acquisition of a majority stake in Misterplan, a technology company based in Cáceres specialising in software solutions for the management and marketing of accommodation, activities and destinations...

Do you want to sell or buy a company?

We are experts in M&A transactions in the technology sector.

Subscribe to our newsletter

    On which topic would you like to receive information?

    Request for information

    If you want to buy or sell a company, or need more information about our services, do not hesitate to contact us through the form.

    Or if you prefer, call us at:

    +34 946 42 41 42